Cambridge University Press 978-0-521-76431-5 - Ethics and the Business of Biomedicine Edited by Denis G. Arnold Frontmatter More information

ETHICS AND THE BUSINESS OF BIOMEDICINE

During the last thirty years we have witnessed sweeping changes in healthcare worldwide, including new and expensive biomedical technologies, an increasingly powerful and influential pharmaceutical industry, steadily increasing healthcare costs in industrialized nations, and new threats to medical professionalism. The essays collected in this book concern costs and profits in relation to just healthcare, the often controversial practices of pharmaceutical companies, and corruption in the professional practice of medicine. Leading experts discuss justice in relation to business-friendly strategies in the delivery of healthcare, access to life-saving drugs, the ethics of pharmaceutical company marketing practices, exploitation in drug trials, and undue industry influence over medicine. They offer guidance regarding the ethical delivery of healthcare products and services by profit-seeking organizations operating in a global marketplace, and recommend pragmatic solutions to enhance organizational integrity and curb medical corruption in the interest of patient welfare.

DENIS G. ARNOLD is the Jule and Marguerite Surtman Distinguished Scholar in Business Ethics at Belk College of Business, University of North Carolina, Charlotte. Formerly he was Associate Professor of Philosophy and Director of the Center for Applied and Professional Ethics at the University of Tennessee at Knoxville. He is author of *The Ethics of Global Business* (2009) and co-editor of *Ethical Theory and Business*, 8th Edition (2009) and *Rising Above Sweatshops: Innovative Approaches to Global Labor Challenges* (2003). Cambridge University Press 978-0-521-76431-5 - Ethics and the Business of Biomedicine Edited by Denis G. Arnold Frontmatter More information

ETHICS AND THE BUSINESS OF BIOMEDICINE

EDITED BY

DENIS G. ARNOLD University of North Carolina at Charlotte



© Cambridge University Press

CAMBRIDGE

Cambridge University Press 978-0-521-76431-5 - Ethics and the Business of Biomedicine Edited by Denis G. Arnold Frontmatter More information

> CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, Delhi

> > Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK

Published in the United States of America by Cambridge University Press, New York

www.cambridge.org Information on this title: www.cambridge.org/9780521748223

© Cambridge University Press 2009

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2009

Printed in the United Kingdom at the University Press, Cambridge

A catalog record for this publication is available from the British Library

Library of Congress Cataloging in Publication data Ethics and the business of biomedicine / edited by Denis G. Arnold. p. cm.

Includes bibliographical references and index. ISBN 978-0-521-76431-5

1. Medical ethics. 2. Bioethics. 3. Business ethics. I. Arnold, Denis Gordon. II. Title. R724.E8211115 2009 174'.957-dc22

2009008251

ISBN 978-0-521-76431-5 hardback ISBN 978-0-521-74822-3 paperback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party Internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

CAMBRIDGE

Cambridge University Press 978-0-521-76431-5 - Ethics and the Business of Biomedicine Edited by Denis G. Arnold Frontmatter More information

Contents

List of figures List of contributors Acknowledgements		<i>page</i> vii viii x
	Introduction	I
I	Medicine and the market Daniel Callahan	20
2	Broken promises: do business-friendly strategies frustrate just healthcare? <i>Norman Daniels</i>	35
3	Are patents an efficient and internationally fair means of funding research & development for new medicines? <i>Paul T. Menzel</i>	62
4	The exploitation of the economically disadvantaged in pharmaceutical research <i>Tom L. Beauchamp</i>	83
5	The dangers of detailing: how pharmaceutical marketing threatens healthcare <i>Jason E. Hubbard</i>	103
6	The ethics of direct-to-consumer pharmaceutical advertising <i>Denis G. Arnold</i>	131
7	Industry-funded bioethics and the limits of disclosure <i>Carl Elliott</i>	150
8	Two cheers for the pharmaceutical industry <i>Richard T. De George</i>	169

vi	Contents	
9	The third face of medicine: ethics, business and challenges to professionalism Mary Rorty, Patricia Werhane, and Ann Mills	198
IO	Theoretical foundations for organizational ethics: developing norms for a new kind of healthcare <i>George Khushf</i>	220
II	A crisis in medical professionalism: time for Flexner II <i>Daniel Wikler</i>	249
Bibliography Index		260 283

CAMBRIDGE

Cambridge University Press 978-0-521-76431-5 - Ethics and the Business of Biomedicine Edited by Denis G. Arnold Frontmatter More information

Figures

9.1	Standard stakeholder map	<i>page</i> 208
9.2	Prioritized stakeholder map	210
9.3	Organizational ethics model	213
II.I	Cartoon, The New Yorker, July 7 and 14, 2008, 64, © The	
	New Yorker Collection 2008 Paul Noth from cartoonbank.	
	com. All Rights Reserved	252

Contributors

- DENIS G. ARNOLD is the Jule and Marguerite Surtman Distinguished Scholar in Business Ethics at the University of North Carolina at Charlotte.
- TOM L. BEAUCHAMP is Professor of Philosophy and a Senior Research Scholar at the Kennedy Institute of Ethics at Georgetown University.
- DANIEL CALLAHAN is a Co-Founder and Director of International Programs at the Hastings Center, Senior Research Fellow in the Department of Philosophy at Yale University, and Senior Lecturer at Harvard Medical School.
- NORMAN DANIELS is Mary B. Saltonstall Professor and Professor of Ethics and Population Health at Harvard University.
- RICHARD T. DE GEORGE is University Distinguished Professor of Philosophy, of Russian and East European Studies, and of Business Administration, and Co-Director of the International Center for Ethics in Business at the University of Kansas.
- CARL ELLIOTT is Professor in the Center for Bioethics, Professor of Pediatrics, and Professor of Philosophy at the University of Minnesota, Twin Cities.
- JASON HUBBARD is a doctoral student in philosophy and an M.B.A. student at the University of Tennessee at Knoxville.
- PAUL T. MENZEL is Provost Emeritus and Professor of Philosophy Emeritus at Pacific Lutheran University.
- GEORGE KHUSHF is Associate Professor of Philosophy and Humanities Director at the Center for Bioethics at the University of South Carolina.

List of contributors

ix

- ANN E. MILLS is Associate Professor at the Center for Biomedical Ethics, Associate Professor of Medical Education, and Co-Director of the Program in Ethics and Policy in Health Care at the University of Virginia.
- MARY V. RORTY is a Faculty Associate at the Center for Biomedical Ethics at Stanford University.
- PATRICIA H. WERHANE is the Wicklander Chair of Business Ethics and Director of the Institute for Business and Professional Ethics at DePaul University and Peter and Adeline Ruffin Professor of Business Ethics and Senior Fellow at of the Olsson Center for Applied Ethics in the Darden School at the University of Virginia.
- DANIEL WIKLER is Mary B. Saltonstall Professor and Professor of Ethics and Population Health at Harvard University.

Cambridge University Press 978-0-521-76431-5 - Ethics and the Business of Biomedicine Edited by Denis G. Arnold Frontmatter More information

Acknowledgements

The papers collected in this volume derive from a conference sponsored by the Center for Applied and Professional Ethics and the Department of Philosophy at the University of Tennessee. This conference brought together in Knoxville leading bioethicists and business ethicists to discuss issues such as costs and profits in relation to just healthcare, the influence of industry over the practice of medicine and over bioethics, the obligations of pharmaceutical companies to citizens of developing nations, and related themes. In addition to the contributors to this volume, I am grateful to many conference participants for their intellectual contributions. Special thanks are due to Alfred Beasley, Norman Bowie, George Brenkert, Glenn Graber, John Hardwig, E. Haavi Morreim, Gary Pulsinelli, Charlie Reynolds, Michael Stahl, and Laurie Zoloth.

The conference received the generous support of many academic units at Tennessee including the College of Arts and Sciences, the College of Business, the Office of the Chancellor, the Office of Research, the Law School, and the Baker Center for Public Policy. Special thanks in this regard are due to John Hardwig, Bruce Bursten, and Jan Williams. I am grateful to Ann Beardsley and Susan Williams for their capable administrative support.

Many thanks also to the students in my doctoral seminar on the topic of this volume for their penetrating questions and excellent discussion of these issues. Thanks in particular to Todd Johnson and Tom Harter for their help with the book. Special thanks to Jason Hubbard for his excellent research assistance and cheerful embrace of every assigned task. Hilary Gaskin at Cambridge was an early and enthusiastic supporter of this project. Her patience and dedication to the highest standards of publishing are much appreciated. For their love, support, and patience with this project I am especially grateful to Sara Arnold, M.D., and to Skye.